Effectiveness and safety of eravacycline-based regimens for resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.
Shahd Mohammad, Eman Awwad, Ayah Hajjar et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness and safety of eravacycline-based regimens in adults with resistant Acinetobacter baumannii infections. The analysis included 15 studies with 462 patients, predominantly older adults. No significant differences were found in all-cause mortality (RR 1.06; 95% CI 0.46-2.47), clinical cure (RR 0.90; 95% CI 0.77-1.07), or microbiological eradication (RR 0.88; 95% CI 0.56-1.37) compared to non-eravacycline regimens.
Key findings
- No significant difference in all-cause mortality between eravacycline and non-eravacycline regimens (RR 1.06; 95% CI 0.46-2.47).
- Clinical cure rates were similar for eravacycline and non-eravacycline regimens (RR 0.90; 95% CI 0.77-1.07).
- Microbiological eradication rates did not differ significantly (RR 0.88; 95% CI 0.56-1.37).
- Carbapenem-resistant A. baumannii accounted for 84.4% of evaluable cases.
Why it matters
The findings provide important insights into the use of eravacycline for treating multidrug-resistant A. baumannii infections, a significant concern in healthcare settings. Understanding its effectiveness compared to standard regimens can guide treatment decisions in challenging cases.